CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death
Summary: The identification of patients with coronavirus disease 2019 and high risk of severe disease is a challenge in routine care. We performed cell phenotypic, serum, and RNA sequencing gene expression analyses in severe hospitalized patients (n = 61). Relative to healthy donors, results showed...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-07-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004221006799 |
| _version_ | 1818671478362603520 |
|---|---|
| author | Yves Lévy Aurélie Wiedemann Boris P. Hejblum Mélany Durand Cécile Lefebvre Mathieu Surénaud Christine Lacabaratz Matthieu Perreau Emile Foucat Marie Déchenaud Pascaline Tisserand Fabiola Blengio Benjamin Hivert Marine Gauthier Minerva Cervantes-Gonzalez Delphine Bachelet Cédric Laouénan Lila Bouadma Jean-François Timsit Yazdan Yazdanpanah Giuseppe Pantaleo Hakim Hocini Rodolphe Thiébaut |
| author_facet | Yves Lévy Aurélie Wiedemann Boris P. Hejblum Mélany Durand Cécile Lefebvre Mathieu Surénaud Christine Lacabaratz Matthieu Perreau Emile Foucat Marie Déchenaud Pascaline Tisserand Fabiola Blengio Benjamin Hivert Marine Gauthier Minerva Cervantes-Gonzalez Delphine Bachelet Cédric Laouénan Lila Bouadma Jean-François Timsit Yazdan Yazdanpanah Giuseppe Pantaleo Hakim Hocini Rodolphe Thiébaut |
| author_sort | Yves Lévy |
| collection | DOAJ |
| description | Summary: The identification of patients with coronavirus disease 2019 and high risk of severe disease is a challenge in routine care. We performed cell phenotypic, serum, and RNA sequencing gene expression analyses in severe hospitalized patients (n = 61). Relative to healthy donors, results showed abnormalities of 27 cell populations and an elevation of 42 cytokines, neutrophil chemo-attractants, and inflammatory components in patients. Supervised and unsupervised analyses revealed a high abundance of CD177, a specific neutrophil activation marker, contributing to the clustering of severe patients. Gene abundance correlated with high serum levels of CD177 in severe patients. Higher levels were confirmed in a second cohort and in intensive care unit (ICU) than non-ICU patients (P < 0.001). Longitudinal measurements discriminated between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care. |
| first_indexed | 2024-12-17T07:24:38Z |
| format | Article |
| id | doaj.art-61e089ec34614597aa6b9bb37427c685 |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-12-17T07:24:38Z |
| publishDate | 2021-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-61e089ec34614597aa6b9bb37427c6852022-12-21T21:58:40ZengElsevieriScience2589-00422021-07-01247102711CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and deathYves Lévy0Aurélie Wiedemann1Boris P. Hejblum2Mélany Durand3Cécile Lefebvre4Mathieu Surénaud5Christine Lacabaratz6Matthieu Perreau7Emile Foucat8Marie Déchenaud9Pascaline Tisserand10Fabiola Blengio11Benjamin Hivert12Marine Gauthier13Minerva Cervantes-Gonzalez14Delphine Bachelet15Cédric Laouénan16Lila Bouadma17Jean-François Timsit18Yazdan Yazdanpanah19Giuseppe Pantaleo20Hakim Hocini21Rodolphe Thiébaut22Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France; Corresponding authorVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France; Univ. Bordeaux, Department of Public Health, INSERM U1219 Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, 146 Rue Leo Saignat, 33076 Bordeaux, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France; Univ. Bordeaux, Department of Public Health, INSERM U1219 Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, 146 Rue Leo Saignat, 33076 Bordeaux, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceSwiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, SwitzerlandVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceUniv. Bordeaux, Department of Public Health, INSERM U1219 Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, 146 Rue Leo Saignat, 33076 Bordeaux, FranceUniv. Bordeaux, Department of Public Health, INSERM U1219 Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, 146 Rue Leo Saignat, 33076 Bordeaux, FranceAP-HP, Hôpital Bichat, Département Épidémiologie Biostatistiques et Recherche Clinique, INSERM, Centre d’Investigation clinique-Epidémiologie Clinique 1425, F-75018 Paris, France; AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018 Paris, France; Université de Paris, INSERM, IAME UMR 1137, F-75018 Paris, FranceAP-HP, Hôpital Bichat, Département Épidémiologie Biostatistiques et Recherche Clinique, INSERM, Centre d’Investigation clinique-Epidémiologie Clinique 1425, F-75018 Paris, France; Université de Paris, INSERM, IAME UMR 1137, F-75018 Paris, FranceAP-HP, Hôpital Bichat, Département Épidémiologie Biostatistiques et Recherche Clinique, INSERM, Centre d’Investigation clinique-Epidémiologie Clinique 1425, F-75018 Paris, France; Université de Paris, INSERM, IAME UMR 1137, F-75018 Paris, FranceAPHP- Hôpital Bichat – Médecine Intensive et Réanimation des Maladies Infectieuses, Paris, FranceAPHP- Hôpital Bichat – Médecine Intensive et Réanimation des Maladies Infectieuses, Paris, FranceAP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018 Paris, France; Université de Paris, INSERM, IAME UMR 1137, F-75018 Paris, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France; Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Immunology and Allergy Service, Department of Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, SwitzerlandVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, FranceVaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Hopital Henri Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France; Univ. Bordeaux, Department of Public Health, INSERM U1219 Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, 146 Rue Leo Saignat, 33076 Bordeaux, France; CHU de Bordeaux, Pôle de Santé Publique, Service d’Information Médicale, Bordeaux, France; Corresponding authorSummary: The identification of patients with coronavirus disease 2019 and high risk of severe disease is a challenge in routine care. We performed cell phenotypic, serum, and RNA sequencing gene expression analyses in severe hospitalized patients (n = 61). Relative to healthy donors, results showed abnormalities of 27 cell populations and an elevation of 42 cytokines, neutrophil chemo-attractants, and inflammatory components in patients. Supervised and unsupervised analyses revealed a high abundance of CD177, a specific neutrophil activation marker, contributing to the clustering of severe patients. Gene abundance correlated with high serum levels of CD177 in severe patients. Higher levels were confirmed in a second cohort and in intensive care unit (ICU) than non-ICU patients (P < 0.001). Longitudinal measurements discriminated between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.http://www.sciencedirect.com/science/article/pii/S2589004221006799immunologyvirology |
| spellingShingle | Yves Lévy Aurélie Wiedemann Boris P. Hejblum Mélany Durand Cécile Lefebvre Mathieu Surénaud Christine Lacabaratz Matthieu Perreau Emile Foucat Marie Déchenaud Pascaline Tisserand Fabiola Blengio Benjamin Hivert Marine Gauthier Minerva Cervantes-Gonzalez Delphine Bachelet Cédric Laouénan Lila Bouadma Jean-François Timsit Yazdan Yazdanpanah Giuseppe Pantaleo Hakim Hocini Rodolphe Thiébaut CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death iScience immunology virology |
| title | CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death |
| title_full | CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death |
| title_fullStr | CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death |
| title_full_unstemmed | CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death |
| title_short | CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death |
| title_sort | cd177 a specific marker of neutrophil activation is associated with coronavirus disease 2019 severity and death |
| topic | immunology virology |
| url | http://www.sciencedirect.com/science/article/pii/S2589004221006799 |
| work_keys_str_mv | AT yveslevy cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT aureliewiedemann cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT borisphejblum cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT melanydurand cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT cecilelefebvre cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT mathieusurenaud cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT christinelacabaratz cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT matthieuperreau cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT emilefoucat cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT mariedechenaud cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT pascalinetisserand cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT fabiolablengio cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT benjaminhivert cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT marinegauthier cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT minervacervantesgonzalez cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT delphinebachelet cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT cedriclaouenan cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT lilabouadma cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT jeanfrancoistimsit cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT yazdanyazdanpanah cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT giuseppepantaleo cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT hakimhocini cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath AT rodolphethiebaut cd177aspecificmarkerofneutrophilactivationisassociatedwithcoronavirusdisease2019severityanddeath |